<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04967287</url>
  </required_header>
  <id_info>
    <org_study_id>MyopiaX-1</org_study_id>
    <nct_id>NCT04967287</nct_id>
  </id_info>
  <brief_title>MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation</brief_title>
  <acronym>MyopiaX-1</acronym>
  <official_title>MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dopavision GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dopavision GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate the safety and efficacy of MyopiaX - a digital&#xD;
      treatment intended to slow the progression of myopia in children and adolescent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study is a multicentric, randomized controlled, double masked trial to&#xD;
      investigate the safety and efficacy of MyopiaX, a digital treatment to slow myopia&#xD;
      progression as compared to a sham treatment.&#xD;
&#xD;
      The trial consists of a 24 month active treatment period followed by a 12 month- treatment&#xD;
      free follow-up. 234 children and adolescent aged 6 - 14 years will be included in the trial.&#xD;
      Eligible subjects will be randomly assigned in a 2:1 distribution to either the treatment or&#xD;
      the sham group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 19, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in spherical equivalent refraction</measure>
    <time_frame>24 months</time_frame>
    <description>Change in spherical equivalent refraction (D) from baseline to 24 months as measured by cycloplegic autorefraction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in axial length</measure>
    <time_frame>24 months</time_frame>
    <description>Change in axial length (mm) from baseline to 24 months as measured by optical biometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in spherical equivalent refraction</measure>
    <time_frame>12 months</time_frame>
    <description>Change in spherical equivalent refraction (D) from baseline to 12 months as measured by cycloplegic autorefraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in axial length</measure>
    <time_frame>6, 12, and 18 months</time_frame>
    <description>Changes in axial length (mm) from baseline to 6, 12, and18 months as measured by optical biometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parent reported outcome - satisfaction with MyopiaX</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Questionnaire created to evaluate parents satisfaction with the device and treatment concept</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>MyopiaX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MyopiaX treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham comparator using the same device and components but without the actual treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MyopiaX</intervention_name>
    <description>MyopiaX treatment twice a day</description>
    <arm_group_label>MyopiaX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Sham device usage twice a day</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Myopic children (-0.75 to -5.0 D SER, least myopic meridian -0.50 D in each eye)&#xD;
&#xD;
          -  At least BCVA 0.2 LogMAR in each eye&#xD;
&#xD;
          -  Age: 6 - 14 years old&#xD;
&#xD;
          -  Evidence of myopia progression over the preceding year (≤ -0.25 D /year at least)&#xD;
&#xD;
          -  Good tolerability of test session with VR system&#xD;
&#xD;
          -  Binocular adequacy as tested with VR&#xD;
&#xD;
          -  Ability to understand treatment and give valid assent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant or previous therapies for myopia&#xD;
&#xD;
          -  Eye diseases/conditions:&#xD;
&#xD;
          -  Anisometropia ≥ 1.5 D&#xD;
&#xD;
          -  Astigmatism ≥ 3 D&#xD;
&#xD;
          -  Ophthalmological comorbidities&#xD;
&#xD;
          -  Optic nerve abnormalities&#xD;
&#xD;
          -  Suspicion of syndromic or monogenetic myopia&#xD;
&#xD;
          -  Systemic illnesses affecting eye health, eye growth, and/or refraction&#xD;
&#xD;
          -  Any illnesses affecting dopamine function (e.g., sleep disorder)&#xD;
&#xD;
          -  Medication affecting dopamine function, accommodation, pupil size, or having an impact&#xD;
             on the ocular surface (such as allergy medications)&#xD;
&#xD;
          -  Participation in other clinical studies&#xD;
&#xD;
          -  Medical history (or family history) of photosensitive epilepsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Flitcroft, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Centre for Eye Reserach Ireland, Technological University Dublin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ida Zuendorf, PhD</last_name>
    <phone>+49 17620904189</phone>
    <email>zuendorf@dopavision.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clinical Trials</last_name>
    <email>clinicaltrials@dopavision.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MVZ Makula-Netzhaut-Zentrum Breyer Kaymak Klabe</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Eye Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Eye Research Ireland</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <contact>
      <last_name>James Loughman, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minho</name>
      <address>
        <city>Braga</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Complutense of Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Digital treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

